Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce Sells 1,998 Shares
Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the completion of the transaction, the senior vice president now directly owns 27,246 shares in the company, valued at $2,574,202.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Richard Paul Bryce also recently made the following trade(s):
- On Monday, July 3rd, Richard Paul Bryce sold 5,000 shares of Puma Biotechnology stock. The stock was sold at an average price of $87.10, for a total value of $435,500.00.
Puma Biotechnology Inc (NYSE PBYI) traded up 1.64% during midday trading on Monday, reaching $95.85. The company had a trading volume of 1,277,640 shares. The firm has a 50-day moving average of $84.95 and a 200-day moving average of $50.35. Puma Biotechnology Inc has a 12 month low of $28.35 and a 12 month high of $97.14. The stock’s market cap is $3.54 billion.
Puma Biotechnology (NYSE:PBYI) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.06) by $0.09. On average, equities analysts expect that Puma Biotechnology Inc will post ($8.43) EPS for the current fiscal year.
Several analysts recently weighed in on PBYI shares. Bank of America Corporation restated a “buy” rating and set a $117.00 target price (up previously from $100.00) on shares of Puma Biotechnology in a research note on Friday. Cowen and Company reiterated an “outperform” rating and issued a $120.00 price objective (up previously from $91.00) on shares of Puma Biotechnology in a research report on Saturday. Leerink Swann reissued an “outperform” rating and issued a $125.00 target price (up from $115.00) on shares of Puma Biotechnology in a report on Wednesday, July 19th. Citigroup Inc. reissued a “buy” rating and issued a $105.00 target price on shares of Puma Biotechnology in a report on Friday, June 30th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $105.00 price target on shares of Puma Biotechnology in a report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $101.75.
Hedge funds have recently bought and sold shares of the stock. Creative Planning boosted its stake in shares of Puma Biotechnology by 62.3% in the second quarter. Creative Planning now owns 2,862 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 1,099 shares during the period. Bank of Montreal Can boosted its position in Puma Biotechnology by 1.8% in the second quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 97 shares during the period. Fox Run Management L.L.C. bought a new position in Puma Biotechnology during the second quarter worth about $227,000. Credit Suisse AG boosted its position in Puma Biotechnology by 97.9% in the first quarter. Credit Suisse AG now owns 82,644 shares of the biopharmaceutical company’s stock worth $3,075,000 after buying an additional 40,890 shares during the period. Finally, Redmile Group LLC boosted its position in Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock worth $64,185,000 after buying an additional 435,274 shares during the period. Institutional investors and hedge funds own 80.98% of the company’s stock.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.